521 results on '"Lus, Giacomo"'
Search Results
2. Disability trajectories by progression independent of relapse activity status differ in pediatric, adult and late-onset multiple sclerosis
3. Pediatric-onset Multiple Sclerosis treatment: a multicentre observational study comparing natalizumab with fingolimod
4. Progression independent of relapse activity in relapsing multiple sclerosis: impact and relationship with secondary progression
5. Ocrelizumab and ofatumumab comparison: an Italian real-world propensity score matched study
6. Correction to: Progression independent of relapse activity in relapsing multiple sclerosis: impact and relationship with secondary progression
7. Late-onset multiple sclerosis: disability trajectories in relapsing–remitting patients of the Italian MS Registry
8. Evaluation of drivers of treatment switch in relapsing multiple sclerosis: a study from the Italian MS Registry
9. COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patients
10. Effectiveness of Ocrelizumab in Primary Progressive Multiple Sclerosis: a Multicenter, Retrospective, Real-world Study (OPPORTUNITY)
11. Effectiveness of teriflunomide on No Evidence of Disease Activity and cognition in relapsing remitting multiple sclerosis: results of the NEDA3PLUS study
12. Long-term effectiveness of natalizumab in secondary progressive multiple sclerosis: A propensity-matched study
13. The multidimensional assessment of body representation and interoception in multiple sclerosis
14. NEDA-3 achievement in early highly active relapsing remitting multiple sclerosis patients treated with Ocrelizumab or Natalizumab
15. Disease-modifying therapies in managing disability worsening in paediatric-onset multiple sclerosis: a longitudinal analysis of global and national registries
16. Unmet needs and gaps in the identification of secondary progression in multiple sclerosis: a Southern Italy healthcare professionals’ perspective
17. Disease‐Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis
18. Health related quality of life in the domain of physical activity predicts confirmed disability progression in people with relapsing remitting multiple sclerosis
19. Long-term follow-up (up to 11 years) of an Italian pediatric MS cohort treated with Natalizumab: a multicenter, observational study
20. Validation of an iPad version of the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS)
21. Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 Pandemic
22. Predictors of Cladribine Effectiveness and Safety in Multiple Sclerosis: A Real-World, Multicenter, 2-Year Follow-Up Study
23. Long-term effectiveness of natalizumab in secondary progressive multiple sclerosis: A propensity-matched study
24. Covid-19 Outbreak in Italy: An Opportunity to Evaluate Extended Interval Dosing of Ocrelizumab in MS Patients (P2-6.010)
25. Multiple sclerosis and genetic polymorphisms in fibrinogen-mediated hemostatic pathways: a case–control study
26. Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial
27. PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study
28. Disability assessment using Google Maps
29. Radiological Reporting Systems in Multiple Sclerosis.
30. Clinical and Genetic Heterogeneity in a Large Family with Pseudoxanthoma Elasticum: MTHFR and SERPINE1 Variants as Possible Disease Modifiers in Developing Ischemic Stroke
31. MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study
32. Adiponectin in Cerebrospinal Fluid from Patients Affected by Multiple Sclerosis Is Correlated with the Progression and Severity of Disease
33. Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS Register
34. Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study
35. Therapeutic choices and disease activity after 2 years of treatment with cladribine: An Italian multicenter study (CladStop).
36. Influence of Previous Disease-Modifying Drug Exposure on T-Lymphocyte Dynamic in Patients With Multiple Sclerosis Treated With Ocrelizumab
37. Apparently isolated CNS involvement in Erdheim-Chester disease: Case report
38. Ocrelizumab Extended Interval Dosing in Primary Progressive Multiple Sclerosis: An Italian Experience
39. Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control Study
40. COVID-19 Severity in Multiple Sclerosis: Putting Data Into Context
41. Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved?
42. Disease-modifying therapies in managing disability worsening in paediatric-onset multiple sclerosis: a longitudinal analysis of global and national registries
43. Comparing face-to-face and videoconference assessment of the Brief Repeatable Battery of Neuropsychological Tests in people with multiple sclerosis
44. Fingolimod reduces the clinical expression of active demyelinating lesions in MS
45. Correction to: Disability assessment using Google Maps
46. No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study
47. Validation of an iPad version of the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) (P3-3.010)
48. Effects of ocrelizumab on NK cell activation in Relapsing Multiple Sclerosis (P2-3.004)
49. Effectiveness of Ocrelizumab in Primary PrOgRessive mulTiple sclerosis: a mUlticeNter, retrospective, real-world sTudY (OPPORTUNITY)
50. Multiple Sclerosis Progression and Relapse Activity in Children
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.